IDegLira vs. Insulin Glargine Long-Term Glycemic Control Trial in Type 2 Diabetes

Type 2 Diabetes Mellitus (T2DM) is a progressive metabolic disorder characterized by insulin resistance and pancreatic beta-cell dysfunction, leading to chronic hyperglycemia. While oral anti-diabetic drugs are initial mainstays, many patients eventually require insulin therapy as the disease progresses. Traditional insulin regimens, however, can be associated with side effects like hypoglycemia and weight gain. Fixed-ratio co-formulations, such as those combining basal insulin with a GLP-1 receptor agonist, offer a strategy to improve glycemic control while potentially mitigating these adverse effects. Insulin degludec/liraglutide (IDegLira) combines a long-acting basal insulin with a GLP-1 agonist, presenting a potential advantage over basal insulin monotherapy like insulin glargine.

This 104-week clinical trial was designed to compare Insulin Degludec/Liraglutide (IDegLira) against Insulin Glargine (IGlar). The study population comprised insulin-naïve subjects with Type 2 Diabetes Mellitus whose glycemic control was inadequately managed with oral anti-diabetic medications. The primary objective was to evaluate the long-term glycemic control achieved by each treatment. The trial was conducted across multiple continents, including Africa, Asia, Europe, North America, and South America, indicating a large-scale, multi-regional study design. Specific enrollment numbers, exact doses, or administration routes for the compounds were not detailed in the provided information.